BRCA1 and neoplasm: In the future, this will entail simultaneous tumor and blood BRCA NGS testing, and the evaluation of additional predictive biomarkers beyond BRCA1/2 gene alterations, as homologous recombination deficiency (HRD) signatures and immune biomarkers.